International Clinical Trial: A Multicenter, Prospective, Open-Label, Randomized Controlled Study Comparing Single-Dose Versus Fractionated-Dose Regimens of Albumin-Bound Paclitaxel in Neoadjuvant Therapy with Toripalimab Combined with Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131659) titled 'A Multicenter, Prospective, Open-Label, Randomized Controlled Study Comparing Single-Dose Versus Fractionated-Dose Regimens of Albumin-Bound Paclitaxel in Neoadjuvant Therapy with Toripalimab Combined with Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma' on Sept. 4.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Esophageal carcinoma

Intervention: Multiple-dose group:Neoadjuvant Immunotherapy Combined with Chemotherapy (Preoperative, Total of 2 Cycles): 1. Toripalimab: 240 mg per dose, on day 1, ...